ArticleNature2023
Practical recommendations for using ctDNA in clinical decision making.
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07214532 (SIgnatera-Guided Initiation of Adjuvant CDK4/6 Inhibitor in Intermediate Risk HR+ HER2- Breast Cancer), which is not on this map. Cited by 107 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
SIgnatera-Guided Initiation of Adjuvant CDK4/6 Inhibitor in Intermediate Risk HR+ HER2- Breast Cancer
Who cites it
107 citing papers in PubMed, 2 syntheses or guidelines pooled it, 145 citations in OpenAlex.
- Clinical Utility of Circulating Tumour DNA (ctDNA) Analysis for Assessing Completeness of Primary Lesion Resection and Disease Stage in Patients with Melanoma: A Systematic Review.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Assessing Circulating Tumour DNA (ctDNA) as a Biomarker for Anal Cancer Management: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Trial
- Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial.Blood advances · 2024Trial
- Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab.Journal of cancer research and clinical oncology · 2024Trial
- Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation.Signal transduction and targeted therapy · 2024Trial
- Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis.Cancer immunology, immunotherapy : CII · 2024Trial
- Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study.Signal transduction and targeted therapy · 2023Trial
- Metabolic immune checkpoints (MICs) in cancer: from molecular mechanisms to challenges and opportunities in clinical translation.Signal transduction and targeted therapy · 2026Review
- Assessment of MRD and Longitudinal Monitoring of Post-Surgery Biliary Tract Cancer With a Customized ctDNA Panel.Cancer science · 2026Article
- Circulating Cell-free DNA as a biomarker for radiation-induced injury: From mechanistic insights to clinical translation.Cancer metastasis reviews · 2026Review
- Current Evidence for Circulating Tumor DNA in Sarcoma: Challenges and Opportunities for Clinical Application.Journal of surgical oncology · 2026Review
- Circulating tumor DNA-based minimal residual disease-guided adjuvant therapy in solid tumors: Current evidence, clinical trial frameworks, and future directions.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Integrative cfDNA profiling from low-pass whole-genome sequencing enables tissue-of-origin prediction in cancer.Molecular biomedicine · 2026Article
- ctDNA for MRD assessment is prognostic and predictive in newly diagnosed and relapsed/refractory lymphoma.Blood neoplasia · 2026Article
- Circulating Tumor DNA Analysis in Adrenocortical Carcinoma: A Retrospective Cohort Study.Endocrine pathology · 2026Article
- Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma.Molecular oncology · 2026Article
- Multidrug resistance in cancer: current understandings and future perspective.Molecular biomedicine · 2026Review
- The role of circulating tumor DNA in ovarian cancer.Discover oncology · 2026Review
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The continuous improvement in cancer care over the past decade has led to a gradual decrease in cancer-related deaths. This is largely attributed to improved treatment and disease management strategies. Early detection of recurrence using blood-based biomarkers such as circulating tumour DNA (ctDNA) is being increasingly used in clinical practice. Emerging real-world data shows the utility of ctDNA in detecting molecular residual disease and in treatment-response monitoring, helping clinicians to optimize treatment and surveillance strategies. Many studies have indicated ctDNA to be a sensitive and specific biomarker for recurrence. However, most of these studies are largely observational or anecdotal in nature, and peer-reviewed data regarding the use of ctDNA are mainly indication-specific. Here we provide general recommendations on the clinical utility of ctDNA and how to interpret ctDNA analysis in different treatment settings, especially in patients with solid tumours. Specifically, we provide an understanding around the implications, strengths and limitations of this novel biomarker and how to best apply the results in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.